Business Context and Reporting Period
This Form 6-K filing by GSK plc (a global biopharma company) reports a transaction in its own shares. The reporting period covers the month of February 2026, with the specific transaction date being February 19, 2026. The filing was submitted on February 20, 2026.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed under an existing buyback programme via a non-discretionary agreement with BNP Paribas SA.
- Shares Purchased (Feb 19): 470,000 ordinary shares.
- Price Range: Lowest price paid was 2,217.00 GBp; highest price paid was 2,264.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,243.09 GBp.
- Accumulated Purchases (Since Feb 17): 1,300,000 ordinary shares.
- Treasury Shares Held: 241,191,094 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,074,951,475 ordinary shares.
- Treasury Voting Rights: 5.92% of total voting rights.
Material Changes
The primary material change is the reduction of shares in issue and the increase in treasury shares following the repurchase of 470,000 shares on February 19. This transaction is part of a broader buyback activity initiated on February 17, 2026. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a transaction report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q4 Results for 2025. No specific contingencies or unusual items were disclosed in this transaction report.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Confirm the impact of the 5.92% treasury holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q4 Results for the specific risk factors mentioned in the cautionary statement.
- Monitor subsequent filings for the completion status of the non-discretionary agreement with BNP Paribas SA.